NCT07323745 Long-Term Effects of Mobithron Advance on Knee Osteoarthritis Aims to Investigate the Effects of Mobithron Advance on OA Progression
| NCT ID | NCT07323745 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Universiti Sains Malaysia |
| Condition | Osteoarthritis (OA) of the Knee |
| Study Type | INTERVENTIONAL |
| Enrollment | 84 participants |
| Start Date | 2026-05-03 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 84 participants in total. It began in 2026-05-03 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if the Mobithron Advance drug works to treat and slow the progression of osteoarthritis (OA) in patients. It will also learn about the safety and long-term effects of this drug. The main questions it aims to answer are: * Does long-term administration of Mobithron Advance can modify the progression of knee osteoarthritis with Kellgren-Lawrence grade 1 to 3 in HUSM patients? * Does long term usage of Mobithron Advance has safety profile? Researchers will compare the Mobithron Advance drug to a placebo (a look-alike substance that contains no drug) to see if said drug works to treat OA. Participants will: * Undergo pre-study assessment (baseline assessments) during first visit * Take oral Mobithron Advance daily for 1 year * Visit the clinic once at 3 months, 6 months and 12 months intervals from the initial visit for follow up assessments
Eligibility Criteria
Inclusion Criteria: * Males and female patients above 50 years old at the time of recruitment. * OA Diagnosis: Patients with one or both knee osteoarthritis according to clinical and radiological criteria of the American College of Rheumatology (ACR). * OA Grade: Kellgren Lawrence grade 1-3 Exclusion Criteria: * Secondary arthritis (e.g., rheumatoid arthritis, psoriatic arthritis). * History of joint surgery. * Patients who received steroid injection treatment within the last 3 months or hyaluronic acid injection treatment within the last 6 months. * Contraindications to Mobithron Advance (e.g., known allergies, severe liver or kidney disease). * Patients planning for knee surgery within the research period. * Patients on pharmacological treatment for osteoarthritis, other than rescue analgesic agent, e.g: glucosamine, chondroitin, oral steroid
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07323745 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Osteoarthritis (OA) of the Knee. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07323745 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07323745 currently recruiting?
Yes, NCT07323745 is actively recruiting participants. Contact the research team at anas.alfian92@gmail.com for enrollment information.
Where is the NCT07323745 trial being conducted?
This trial is being conducted at Kota Bharu, Malaysia.
Who is sponsoring the NCT07323745 clinical trial?
NCT07323745 is sponsored by Universiti Sains Malaysia. The trial plans to enroll 84 participants.